Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its ...

Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis. Abelacimab is a fully human ...

Novartis NOVN0.47%increase; green up pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline.

Anthos Therapeutics, launched by Blackstone Life Sciences (BX) and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis. Abelacimab is a novel ...

Blackstone Life Sciences committed $250 million to set up Anthos with Novartis in 2019. Buying Anthos will move Novartis back into competition with other developers of factor XI candidates.

At its founding in 2019 by Blackstone Life Sciences and Novartis, Anthos gained the rights from Novartis to develop abelacimab, a drug targeting stroke prevention and blood clots in those with ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor ...

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.

Novartis started Anthos with Blackstone Inc.'s life sciences arm. Novartis is looking to bolster its cardiology portfolio, with its top-selling heart medicine Entresto confronting generic ...

Anthos Therapeutics, founded in 2019 by Blackstone Life Sciences and Novartis, specializes in developing treatments for cardiovascular diseases. As part of its launch, Anthos obtained the rights ...